<DOC>
	<DOCNO>NCT00310076</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth tumor cell block blood flow tumor . Giving thalidomide surgery chemotherapy may kill remain tumor cell . PURPOSE : This phase II trial study well thalidomide work treat patient undergone surgery receive chemotherapy directly abdomen hyperthermic perfusion cancer spread throughout abdomen due colorectal cancer appendix cancer .</brief_summary>
	<brief_title>Thalidomide Treating Patients Who Have Undergone Surgery Chemotherapy Cancer That Has Spread Throughout Abdomen Due Colorectal Cancer Appendix Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time progression surgery patient undergo cytoreductive surgery intraperitoneal hyperthermic chemotherapy peritoneal carcinomatosis adenomucinosis secondary colorectal appendiceal cancer treat adjuvant thalidomide . Secondary - Estimate progression-free survival probability patient treat regimen . - Obtain toxicity data patient receive long-term oral thalidomide therapy . OUTLINE : Patients receive oral thalidomide daily day 1-28 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 12 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm peritoneal carcinomatosis adenomucinosis secondary colorectal appendiceal cancer Underwent cytoreductive surgery intraperitoneal hyperthermic chemotherapy ( IPHC ) within past 12 week Patients residual disease evidence disease IPHC eligible No extraabdominal disease parenchymal liver metastases PATIENT CHARACTERISTICS : ECOG performance status 03 Free infection postoperative complication Hemoglobin &gt; 8.0 g/dL Absolute neutrophil count &gt; 1,000/mm³ Platelet count &gt; 100,000/mm³ PTT PT &lt; 1.5 time normal ( except patient receive therapeutic anticoagulant therapy nonrelated medical condition , atrial fibrillation ) Bilirubin &lt; 1.5 mg/dL OR direct bilirubin ≤ 1.0 mg/dL ( patient Gilbert 's syndrome ) AST/ALT ≤ 2.5 time normal Serum creatinine &lt; 2.0 mg/dL No peripheral neuropathy &gt; grade 1 , except localize neuropathy due mechanical cause trauma Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception 4 month prior , , 4 month treatment thalidomide No history hepatic cirrhosis No history severe hypothyroidism No history medical problem severe congestive heart failure active ischemic heart disease No malignancy within past 5 year except nonmelanoma skin cancer No known history deep vein thrombosis pulmonary embolus PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy , biologic therapy , radiotherapy ( except IPHC ) No concurrent systemic therapy No concurrent high level sedatives No concurrent sedate `` recreational '' drug alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>carcinoma appendix</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>